This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q47603679
rdf:type
wikibase:Item
schema:description
artikulong pang-agham artigo científico (publicado na 2017) tieteellinen artikkeli article scientific 2017年學術文章 vitskapeleg artikkel articol științific სამეცნიერო სტატია научная статья 2017年の論文 naučni članak επιστημονικό άρθρο article scientifique (publié 2017) 2017年學術文章 2017年學術文章 2017年学术文章 vědecký článek 2017年学术文章 2017年學術文章 наукова стаття, опублікована в жовтні 2017 scientific article مقالة علمية научни чланак vetenskaplig artikel wetenschappelijk artikel artigo científico 2017年学术文章 artigo científico (publicado na 2017) scienca artikolo מאמר מדעי articolo scientifico artículu científicu บทความทางวิทยาศาสตร์ bài báo khoa học ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ мақолаи илмӣ teaduslik artikkel tudományos cikk artikull shkencor mokslinis straipsnis мақолаи илмӣ wissenschaftlicher Artikel vedecký článok artykuł naukowy 2017年學術文章 научна статия videnskabelig artikel (udgivet 2017) 2017 nî lūn-bûn 2017年学术文章 سائنسی مضمون գիտական հոդված 2017年學術文章 2017년 논문 научни чланак vitenskapelig artikkel 2017年学术文章 bilimsel makale مقالهٔ علمی artículo científico publicado en 2017 article científic
p:P577
wds:Q47603679-FCBE2BBC-F0C2-46F7-86A4-F8B6612E715F
wdt:P577
2017-10-23T00:00:00Z
p:P407
wds:Q47603679-C551C8D1-078E-4A26-9D77-54E1D51DE565
wdt:P407
wd:Q1860
p:P2860
wds:Q47603679-D189C336-ACB4-4110-96CB-FA75E0AD2419 wds:Q47603679-FDD714B0-4B4E-4E63-A209-2A17412E55A8 wds:Q47603679-077FFA07-5D43-4B29-B323-A7E21A420FE7 wds:Q47603679-0F66A8A5-ED03-49EA-B370-7EF6A50B6BA8 wds:Q47603679-568304B1-FDFD-4161-9FD6-081076966880 wds:Q47603679-80C75D57-2DE9-4B67-807C-AFE36C027609 wds:Q47603679-89300595-116F-4AC9-997D-C4AB6C22D2EA wds:Q47603679-B067F484-BDF1-408B-9B8C-8A56EF343A55 wds:Q47603679-195C5F7C-1173-483C-922E-70055A72495C wds:Q47603679-278760BB-7EF5-4343-A110-2CB041DEA636
wdt:P2860
wd:Q35538245 wd:Q36100521 wd:Q27001240 wd:Q45226069 wd:Q40375140 wd:Q53118691 wd:Q34415766 wd:Q43035164 wd:Q37500066 wd:Q42150449
p:P2093
wds:Q47603679-EEE2BF24-4BE9-4CBE-B879-23CD86D057F9 wds:Q47603679-6540DF63-F8BF-41AB-837E-64656EAFFF6E wds:Q47603679-291BA59D-7205-43BA-BC1B-F70A5764FCB3 wds:Q47603679-2521D00C-0F08-4BF8-83C8-7A85F3DAB670 wds:Q47603679-074FBA3B-E5A6-4422-A89B-3B1A08B0D560
wdt:P2093
Lisa K Naeger Kirk Chan-Tack Debra Birnkrant Karen Qi Kimberly Struble
rdfs:label
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
skos:prefLabel
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
schema:name
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
p:P1476
wds:Q47603679-B316D1EB-037A-4AF7-A408-813356B3A356
wdt:P1476
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
p:P31
wds:Q47603679-4CC3FE63-AC8B-40C1-A711-C5A3599AF8CA
wdt:P31
wd:Q13442814
p:P921
wds:Q47603679-51B75516-E9AC-491F-9DCA-15D27BF910E5 wds:Q47603679-976F66A1-FD89-463B-A8D1-F30754BBC240
wdt:P921
wd:Q2502747 wd:Q708693
p:P698
wds:Q47603679-E870A427-FF1C-459E-88A7-46BA0394CD7F
wdtn:P698
n12:29059462
wdt:P698
29059462
p:P1433
wds:Q47603679-35AF59D5-22D0-487C-865A-C4AE15489E2D
wdt:P1433
wd:Q15724398
p:P356
wds:Q47603679-2262CE1E-C6D6-4461-8D75-F8FC520CEC1C
wdtn:P356
n11:HEP.29601
wdt:P356
10.1002/HEP.29601